{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:47:53Z","timestamp":1794973673607,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Schimmelpenning-Feuerstein-Mims syndrome (SFMS) is a rare mosaic RASopathy associated with epidermal nevi, neurological abnormalities, and increased cancer risk. We report a 2-year-old girl with\n                    <jats:italic>HRAS<\/jats:italic>\n                    -related SFMS, aggressive orbital rhabdomyosarcoma (eRMS) and severe hypophosphatemic rickets resistant to standard therapies. Treatment with the MEK inhibitor trametinib improved phosphate regulation, reducing FGF23 levels, and led to rapid developmental progress, including independent walking. After 29 months, the patient remains in cancer remission with stable phosphate levels. This case highlights trametinib\u2019s potential in managing complex manifestations in SFMS and suggests MEK inhibitors as promising for treating mosaic RASopathies.\n                  <\/jats:p>","DOI":"10.1186\/s13023-025-03801-5","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:42:02Z","timestamp":1751539322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted treatment of hypophosphatemia with trametinib in HRAS-related mosaic RASopathy"],"prefix":"10.1186","volume":"20","author":[{"given":"Adil","family":"Mirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kulozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouzbeh","family":"Banan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semi","family":"Harrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2543-4844","authenticated-orcid":false,"given":"Steffen","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Choukair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"12","key":"3801_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1055\/s-0029-1213358","volume":"87","author":"GW Schimmelpenning","year":"1957","unstructured":"Schimmelpenning GW. Klinischer beitrag Zur symptomatologie der Phakomatosen. Rofo. 1957;87(12):716\u201320. 08\/17 1957. https:\/\/doi.org\/10.1055\/s-0029-1213358","journal-title":"Rofo"},{"issue":"6","key":"3801_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/archpedi.1962.02080030675013","volume":"104","author":"RC Feuerstein","year":"1962","unstructured":"Feuerstein RC, Mims LC. Linear nevus Sebaceus with convulsions and mental retardation. Am J Dis Child. 1962;104(6):675\u20139. https:\/\/doi.org\/10.1001\/archpedi.1962.02080030675013.","journal-title":"Am J Dis Child"},{"key":"3801_CR3","doi-asserted-by":"publisher","unstructured":"van de Warrenburg BPC, van Gulik S, Renier WO, Lammens M, Doelman JC. The linear naevus sebaceus syndrome. Clinical Neurology and Neurosurgery. 1998\/06\/01\/ 1998;100(2):126\u2013132. https:\/\/doi.org\/10.1016\/S0303-8467(98)00012-2","DOI":"10.1016\/S0303-8467(98)00012-2"},{"issue":"1","key":"3801_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1440-0960.2002.00546.x","volume":"43","author":"D Davies","year":"2002","unstructured":"Davies D, Rogers M. Review of neurological manifestations in 196 patients with sebaceous Naevi. Australas J Dermatol. 2002;43(1):20\u20133. https:\/\/doi.org\/10.1046\/j.1440-0960.2002.00546.x.","journal-title":"Australas J Dermatol"},{"key":"3801_CR5","doi-asserted-by":"publisher","unstructured":"Happle R. The group of epidermal nevus syndromes: Part I. Well defined phenotypes. Journal of the American Academy of Dermatology. 2010\/07\/01\/ 2010;63(1):1\u201322. https:\/\/doi.org\/10.1016\/j.jaad.2010.01.017.","DOI":"10.1016\/j.jaad.2010.01.017"},{"issue":"5","key":"3801_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/00001665-200309000-00010","volume":"14","author":"A Santibanez-Gallerani","year":"2003","unstructured":"Santibanez-Gallerani A, Marshall D, Duarte A-M, Melnick SJ, Thaller S. Should nevus Sebaceus of Jadassohn in children be excised? A study of 757 cases, and literature review. J Craniofac Surg. 2003;14(5):658\u201360.","journal-title":"J Craniofac Surg"},{"key":"3801_CR7","doi-asserted-by":"publisher","unstructured":"Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: Part II. Journal of the American Academy of Dermatology. 2009\/10\/01\/ 2009;61(4):563\u2013578. https:\/\/doi.org\/10.1016\/j.jaad.2009.04.059.","DOI":"10.1016\/j.jaad.2009.04.059"},{"key":"3801_CR8","doi-asserted-by":"publisher","unstructured":"Groesser L, Herschberger E, Ruetten A et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nature Genetics. 2012\/07\/01 2012;44(7):783\u2013787. https:\/\/doi.org\/10.1038\/ng.2316","DOI":"10.1038\/ng.2316"},{"issue":"9","key":"3801_CR9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ajmg.a.37135","volume":"167","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Ohashi I, Enomoto Y, et al. A postzygotic NRAS mutation in a patient with schimmelpenning syndrome. Am J Med Genet Part A. 2015;167(9):2223\u20135. https:\/\/doi.org\/10.1002\/ajmg.a.37135.","journal-title":"Am J Med Genet Part A"},{"issue":"12","key":"3801_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/gcc.23092","volume":"61","author":"D Carli","year":"2022","unstructured":"Carli D, Cardaropoli S, Tessaris D, et al. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome. Genes Chromosom Cancer. 2022;61(12):740\u20136. https:\/\/doi.org\/10.1002\/gcc.23092.","journal-title":"Genes Chromosom Cancer"},{"key":"3801_CR11","doi-asserted-by":"publisher","unstructured":"Hebron KE, Hernandez ER, Yohe ME. The rasopathies: from pathogenetics to therapeutics. Dis Models Mech. 2022;15(2). https:\/\/doi.org\/10.1242\/dmm.049107.","DOI":"10.1242\/dmm.049107"},{"issue":"4","key":"3801_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/ajmg.c.32021","volume":"190","author":"D Carli","year":"2022","unstructured":"Carli D, Resta N, Ferrero GB, Ruggieri M, Mussa A. Mosaic rasopathies: A review of disorders caused by somatic pathogenic variants in the genes of the RAS\/MAPK pathway. Am J Med Genet Part C: Seminars Med Genet. 2022;190(4):520\u20139. https:\/\/doi.org\/10.1002\/ajmg.c.32021.","journal-title":"Am J Med Genet Part C: Seminars Med Genet"},{"issue":"1","key":"3801_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-genet-121415-121955","volume":"51","author":"YH Lim","year":"2017","unstructured":"Lim YH, Moscato Z, Choate KA. Mosaicism in cutaneous disorders. Annu Rev Genet. 2017;51(1):123\u201341. https:\/\/doi.org\/10.1146\/annurev-genet-121415-121955.","journal-title":"Annu Rev Genet"},{"issue":"3","key":"3801_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/gcc.23010","volume":"61","author":"NP Agaram","year":"2022","unstructured":"Agaram NP, Huang S-C, Tap WD, Wexler LH, Antonescu CR. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS\/RAF mutations. Genes Chromosom Cancer. 2022;61(3):131\u20137. https:\/\/doi.org\/10.1002\/gcc.23010.","journal-title":"Genes Chromosom Cancer"},{"key":"3801_CR15","doi-asserted-by":"publisher","first-page":"1231434","DOI":"10.3389\/fgene.2023.1231434","volume":"14","author":"R Zuntini","year":"2023","unstructured":"Zuntini R, Cattani C, Pedace L, et al. Case report: sequential postzygotic HRAS mutation and gains of the paternal chromosome 11 carrying the mutated allele in a patient with epidermal nevus and rhabdomyosarcoma: evidence of a multiple-hit mechanism involving HRAS in oncogenic transformation. Front Genet. 2023;14:1231434. https:\/\/doi.org\/10.3389\/fgene.2023.1231434.","journal-title":"Front Genet"},{"issue":"8","key":"3801_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/1346-8138.15922","volume":"48","author":"Q Luo","year":"2021","unstructured":"Luo Q, Zhang Q, Shen J, et al. Expanding mutational spectrum of HRAS by a patient with Schimmelpenning\u2013Feuerstein\u2013Mims syndrome. J Dermatol. 2021;48(8):1273\u20136. https:\/\/doi.org\/10.1111\/1346-8138.15922.","journal-title":"J Dermatol"},{"issue":"2","key":"3801_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/ddt429","volume":"23","author":"YH Lim","year":"2013","unstructured":"Lim YH, Ovejero D, Sugarman JS, et al. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2013;23(2):397\u2013407. https:\/\/doi.org\/10.1093\/hmg\/ddt429.","journal-title":"Hum Mol Genet"},{"key":"3801_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05263-y","author":"C Saint-Laurent","year":"2023","unstructured":"Saint-Laurent C, Mazeyrie L, Yart A, Edouard T. Novel therapeutic perspectives in Noonan syndrome and rasopathies. Eur J Pediatrics. 2023https:\/\/doi.org\/10.1007\/s00431-023-05263-y.","journal-title":"Eur J Pediatrics"},{"key":"3801_CR19","doi-asserted-by":"publisher","unstructured":"Andelfinger G, Marquis C, Raboisson M-J et al. Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition. Journal of the American College of Cardiology. 2019\/05\/07\/ 2019;73(17):2237\u20132239. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.066.","DOI":"10.1016\/j.jacc.2019.01.066"},{"key":"3801_CR20","doi-asserted-by":"publisher","unstructured":"D\u2019Onofrio G, Delrue M-A, Lortie A et al. Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy. Pediatric Neurology. 2023\/11\/01\/ 2023;148:148\u2013151. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.08.019.","DOI":"10.1016\/j.pediatrneurol.2023.08.019"},{"key":"3801_CR21","doi-asserted-by":"publisher","unstructured":"Dori Y, Smith C, Pinto E, et al. Severe lymphatic disorder resolved with MEK Inhibition in a patient with Noonan syndrome and SOS1 mutation. Pediatrics. 2020;146(6). https:\/\/doi.org\/10.1542\/peds.2020-0167.","DOI":"10.1542\/peds.2020-0167"},{"key":"3801_CR22","unstructured":"Sparber-Sauer M. CWS study group\u2013 registries, recommendations and trials. 27.06.2023. Accessed 30.08.2024. https:\/\/www.gpoh.de\/kinderkrebsinfo\/content\/diseases\/solid_tumours\/soft_tissue_sarcomas___tumours\/registres___trials\/index_eng.html"},{"issue":"7","key":"3801_CR23","doi-asserted-by":"publisher","first-page":"e30363","DOI":"10.1002\/pbc.30363","volume":"70","author":"AT Heinz","year":"2023","unstructured":"Heinz AT, Ebinger M, Sch\u00f6nstein A, et al. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: data of the European soft tissue sarcoma registry (SoTiSaR). Pediatr Blood Cancer Jul. 2023;70(7):e30363. https:\/\/doi.org\/10.1002\/pbc.30363.","journal-title":"Pediatr Blood Cancer Jul"},{"key":"3801_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","volume":"61","author":"C Bergwitz","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91\u2013104. https:\/\/doi.org\/10.1146\/annurev.med.051308.111339.","journal-title":"Annu Rev Med"},{"issue":"6","key":"3801_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3390\/life14060731","volume":"14","author":"A Gazzin","year":"2024","unstructured":"Gazzin A, Fornari F, Cardaropoli S, et al. Exploring new drug repurposing opportunities for MEK inhibitors in rasopathies: A comprehensive review of safety, efficacy, and future perspectives of Trametinib and selumetinib. Life. 2024;14(6):731.","journal-title":"Life"},{"issue":"2","key":"3801_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacbts.2024.10.002","volume":"10","author":"CM Wolf","year":"2025","unstructured":"Wolf CM, Zenker M, Boleti O, et al. Impact of MEK Inhibition on childhood RASopathy-Associated hypertrophic cardiomyopathy. JACC: Basic Translational Sci. 2025;10(2):152\u201366. https:\/\/doi.org\/10.1016\/j.jacbts.2024.10.002.","journal-title":"JACC: Basic Translational Sci"},{"issue":"11","key":"3801_CR27","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","volume":"24","author":"PMK de Blank","year":"2022","unstructured":"de Blank PMK, Gross AM, Akshintala S, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neurooncology. 2022;24(11):1845\u201356. https:\/\/doi.org\/10.1093\/neuonc\/noac165.","journal-title":"Neurooncology"},{"key":"3801_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fendo.2020.00338","volume":"11","author":"A Schindeler","year":"2020","unstructured":"Schindeler A, Biggin A, Munns CF. Clinical evidence for the benefits of burosumab therapy for X-Linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne). 2020;11:338. https:\/\/doi.org\/10.3389\/fendo.2020.00338.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3801_CR29","doi-asserted-by":"publisher","unstructured":"Smith P, Bayliss S, Shinawi M, et al. SAT-LB085 first report of burosumab (Anti-FGF23 monoclonal Antibody) for rickets complicating HRAS-Associated cutaneous skeletal hypophosphatemia syndrome. J Endocr Soc. 2019;3(Supplement1). https:\/\/doi.org\/10.1210\/js.2019-SAT-LB085.","DOI":"10.1210\/js.2019-SAT-LB085"},{"issue":"3","key":"3801_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1158\/1940-6207.Capr-09-0068","volume":"3","author":"CE Camalier","year":"2010","unstructured":"Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH, Beck GR. Jr. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res. 2010;3(3):359\u201370. https:\/\/doi.org\/10.1158\/1940-6207.Capr-09-0068.","journal-title":"Cancer Prev Res"},{"issue":"3","key":"3801_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1210\/jc.2012-3473","volume":"98","author":"DE Leaf","year":"2013","unstructured":"Leaf DE, Pereira RC, Bazari H, J\u00fcppner H. Oncogenic osteomalacia due to FGF23-Expressing Colon adenocarcinoma. J Clin Endocrinol Metabolism. 2013;98(3):887\u201391. https:\/\/doi.org\/10.1210\/jc.2012-3473.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"3801_CR32","doi-asserted-by":"publisher","unstructured":"Takashi Y, Kosako H, Sawatsubashi S et al. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proceedings of the National Academy of Sciences. 2019;116(23):11418\u201311427. doi:https:\/\/doi.org\/10.1073\/pnas.1815166116","DOI":"10.1073\/pnas.1815166116"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03801-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03801-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03801-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:42:05Z","timestamp":1751539325000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03801-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3801"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03801-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for individual off-label treatment with trametinib was obtained from the parents. Ethics approval does not apply to individual treatment decisions in Germany. Approval for off-label treatment and recommendations for surveillance and dosing were obtained from the pharmacological review board of Heidelberg University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of data and images was obtained from the parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest relevant to this article to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}